RxDoctor Payments Data

Robert Gioia, DO

Internal Medicine · North Lauderdale, FLNPI 1689022543

Payments from drug & device makers

$3,089in general payments, 2019–2025

Across 100 payments — averaging $30.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$909
  • Novo Nordisk$351
  • Edwards Lifesciences$137
  • AstraZeneca$125
  • Intuitive Surgical$110
  • plus $336 from 9 others

What the payments were for

  • Food & beverage$3,089100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,089 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$29,938
Medicare patients
95
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala29$129,867
DescovyEmtricitabine/Tenofov Alafenam46$111,064
EliquisApixaban39$42,806
OzempicSemaglutide16$19,678
MounjaroTirzepatide14$14,397
Spiriva HandihalerTiotropium Bromide16$12,691
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,165
Testosterone12$1,695
Testosterone Cypionate27$1,595
Novolog FlexpenInsulin Aspart11$1,484
Rosuvastatin Calcium121$1,384
Atorvastatin Calcium158$1,325
Omeprazole65$947
Amlodipine Besylate133$726
Albuterol Sulfate HfaAlbuterol Sulfate32$710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$909$240,93175 claims
Novo NordiskOzempic$351$19,67816 claims
Lilly USA, LLCMounjaro$15$14,39714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in North Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →